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Abstract
Angiotensin-converting enzyme 2 (ACE2) is expressed in the kidney and may be a renoprotective enzyme, since it converts
angiotensin (Ang) II to Ang-(1-7). ACE2 has been detected in urine from patients with chronic kidney disease. We measured
urinary ACE2 activity and protein levels in renal transplant patients (age 54 yrs, 65% male, 38% diabetes, n=100) and
healthy controls (age 45 yrs, 26% male, n=50), and determined factors associated with elevated urinary ACE2 in the
patients. Urine from transplant subjects was also assayed for ACE mRNA and protein. No subjects were taking inhibitors of
the renin-angiotensin system. Urinary ACE2 levels were significantly higher in transplant patients compared to controls
(p=0.003 for ACE2 activity, and p#0.001 for ACE2 protein by ELISA or western analysis). Transplant patients with diabetes
mellitus had significantly increased urinary ACE2 activity and protein levels compared to non-diabetics (p,0.001), while
ACE2 mRNA levels did not differ. Urinary ACE activity and protein were significantly increased in diabetic transplant subjects,
while ACE mRNA levels did not differ from non-diabetic subjects. After adjusting for confounding variables, diabetes was
significantly associated with urinary ACE2 activity (p=0.003) and protein levels (p,0.001), while female gender was
associated with urinary mRNA levels for both ACE2 and ACE. These data indicate that urinary ACE2 is increased in renal
transplant recipients with diabetes, possibly due to increased shedding from tubular cells. Urinary ACE2 could be a marker
of renal renin-angiotensin system activation in these patients.
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Introduction
Angiotensin-converting enzyme 2 (ACE2) is a recently identified
member of the renin-angiotensin system (RAS) that degrades
angiotensin (Ang) II to the seven amino acid peptide fragment
Ang-(1-7) [1,2]. ACE2 is a homologue of angiotensin-converting
enzyme (ACE), but is not blocked by ACE inhibitors. Although
ACE2 is found in many tissues, expression is especially high in the
kidney, particularly within cells of the proximal tubule [3–5]. In
mice deletion of the ACE2 gene is associated with development of
late-stage glomerulosclerosis, and acceleration of diabetic ne-
phropathy, in the absence of hypertension [6,7]. In spontaneously
hypertensive rats, administration of human recombinant ACE2
reduces blood pressure [8], and in diabetic mice, exogenous
human ACE2 diminishes blood pressure and glomerular injury
[9]. Thus, ACE2 may be an endogenous protector against the
progression of chronic kidney disease (CKD).
In kidney tubular epithelial cells, ACE2 is localized to the apical
membrane and also appears in the cytoplasm [3,10]. ACE2 is shed
at its carboxy-terminus from the plasma membrane in cultured
human embryonic kidney cells and airway epithelial cells, a process
catalyzed by the enzyme ‘‘a disintegrin and metalloproteinase-17’’
(ADAM-17) [11–13]. Whether this process occurs in the proximal
tubule is unclear, although soluble ACE2 has been detected in
human urine [10]. In a recent study, urinary levels of ACE2
protein were significantly increased in humans with CKD (the
majority with chronic glomerulonephritis), compared to healthy
controls, as determined by enzyme-linked immunosorbent assay
(ELISA) [14]. Urinary ACE2 was also higher in diabetics with
CKD [14]. These results suggest that ACE2 may be shed into the
urine, and could be a biomarker in CKD patients. However, the
presence of urinary ACE2 has not been studied in renal transplant
recipients, and the factors associated with elevated urinary ACE2
remain unclear. Accordingly, the principle objective of the present
study was to determine if urinary ACE2 activity, protein, and
mRNA can be detected in renal transplant patients, and to identify
factors associated with the presence of ACE2. In addition, we
examined factors associated with urinary ACE activity, protein
and mRNA in these patients. Our data indicate that urinary
ACE2 is increased in renal transplant recipients with diabetes,
possibly due to increased shedding from tubular cells.
Methods
Ethics Statement
This study involved recruitment of human subjects as described
below, with written informed consent, and the study was
conducted according to the principles expressed in the Declaration
of Helsinki. The study protocols were approved by the Research
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200951201H, 200568201H).
Study Subjects
The subjects in this study were 50 healthy controls (age
.18 yrs), recruited from the hospital or research centre staff,
with no history of kidney disease, hypertension, or diabetes, and
100 renal transplant recipients from The Ottawa Hospital Renal
Transplant Program, age .18 yrs, and .3 months post-
transplant. At the time of enrollment, half of the transplant
subjects (n=50) were also enrolled in an ongoing randomized
controlled trial to determine the effect of the ACE inhibitor
ramipril on transplant outcomes (ACE inhibition for the
preservation of renal function and survival in kidney trans-
plantation; International Standard Randomized Controlled Trial
Number Registry ISRCTN-78129473), but had not yet received
either placebo or ramipril. These subjects had documented
significant proteinuria (.200 mg urinary protein/day) at base-
line. The 50 other transplant recipients were patients without
significant proteinuria (spot urine ACR in the normal range, or
,200 mg proteinuria/day). Subjects were excluded if they were
taking ACE inhibitors, angiotensin receptor antagonists, or renin
inhibitors, or if they were pregnant or currently had a urinary
tract infection.
After obtaining informed consent, a spot urine sample was
collected from each subject, and a blood sample was drawn for
measurement of serum creatinine (Cr) and determination of
estimated glomerular filtration rate (eGFR), using the Modification
of Diet in Renal Disease (MDRD) calculation [15]. Demographic
information was obtained via interview with the subject and/or
from the hospital chart. For transplant recipients, a diagnosis of
diabetes mellitus and the primary renal diagnoses were obtained
directly from survey of the hospital chart.
Measurement of Urinary Albumin/Creatinine
Urine samples were placed on ice, aliquoted and then
centrifuged at 12000 g for 5 min at 4uC. Measurements of urinary
albumin were performed on supernatant fractions, using an
ELISA kit (Exocell Inc., Philadelphia, PA, USA). Results were
corrected for urinary Cr concentration, using a kit specific for
human Cr (Creatinine Companion, Exocell Inc.).
Urinary ACE2 and ACE Enzyme Activity Assays
The enzyme activities of urinary ACE2 and ACE were
measured using synthetic substrates, essentially as we previously
reported [16]. All results were corrected for the Cr concentration
in the urine samples. Details on the assays can be found in Text
S1.
Urinary ACE2 ELISA
The amount of ACE2 present in urine specimens was
quantified using a commercial ELISA kit (Cat. No. AG-45A-
0022EK-KI01, AdipoGen, Seoul, Korea) according to the
protocol provided by the supplier (http://www.adipogen.com/
ag-45a-0022/ace2-human-elisa-kit.html). A standard curve was
generated by performing 1:2 serial dilutions of human
recombinant ACE2 (50 ng/ml), provided with the kit, with
the limit of detection ranging from 0.391 to 25 ng/mL. In
preliminary experiments, the average intra-assay coefficient of
variation (CV) for the assay was 2.9%, and the average inter-
assay CV value was 8.7% (n=10). The amount of ACE2
obtained by ELISA was normalized to the subject’s urine Cr
concentration, and is reported as ng/mg Cr.
Urinary ACE2 and ACE Immunoblot Assays
Urine aliquots (supernatant fraction, 15 mL) were subjected to
immunoblot analysis for ACE2 and ACE, using commercially
available antibodies. To control for variations in urine concentra-
tion, the values obtained by densitometry were divided by the
corresponding Cr concentration for that urine sample. Details on
the assays can be found in Text S1.
Peptide N-Glycosidase F (PNGase F) Treatment
Urine aliquots (supernatant fraction, 20 mL) were subject to
deglycosylation reaction using PNGase F (Cat No. P0704S, New
England Biolabs, Ipswich, MA, USA). Deglycosylated urinary
ACE2 protein fragments were detected by western analysis.
Details of the assays can be found in Text S1.
Urinary mRNA Assays
Urine samples (40 mL) were centrifuged at 1000 g for 20 min at
4uC. Total RNA was isolated from pellet fractions and then
subjected to real-time RT-PCR for quantitation of ACE2 and
ACE (see Text S1 for assay details).
Urinary Ang II and Ang-(1-7) Assays
Urinary levels of Ang II were measured using a commercial
peptide radioimmunoassay (RIA) kit that contains an Ang II-
selective polyclonal antibody and
125I-Ang II (Peninsula Labora-
tories, San Carlos, CA, USA), essentially as described [16,17].
Ang-(1-7) levels were measured using a commercial peptide
enzyme immunoassay (EIA) kit that contains an Ang-(1-7)-selective
polyclonal antibody (Peninsula Laboratories) [16]. For assay
details, see Text S1.
Analysis
Data are presented visually as box plots. Continuous variables
are reported as the median value, with the interquartile range in
parentheses. Statistical analysis was performed by the nonpara-
metric Mann-Whitney U test for unpaired samples to compare
data in healthy controls and transplant recipients, and diabetic vs
non-diabetic transplant recipients. A linear regression model was
constructed to identify potential explanatory variables for urinary
ACE2 and ACE levels in the 100 transplant subjects. The
dependent variable was the measure under study (e.g. ACE2
activity) while the following explanatory variables were entered
into the model: age, gender, diabetes, eGFR, albuminuria,
hypertension, and use of calcineurin inhibitors. Variables were
forced in simultaneously and removed from the model if not
statistically significant. Standardized regression coefficients (b) are
presented for each dependent variable in the model. Data were
analyzed using SigmaStat (version 3.01 A; SYSTAT) and JMP
(version 8.0.1, SAS Inc.). For all data, a p value ,0.05 was
considered significant.
Results
Patient Demographics
The characteristics of the 50 healthy controls and 100
transplant subjects are depicted in Table 1. The median age for
control subjects was 45 [interquartile range (IQR), 36–50] yrs, and
26% were male. The median age for transplant subjects was 54
(IQR, 42–62) yrs, 65% were male, 38% had diabetes, and 88%
had hypertension. Median time from transplant was 3 (IQR, 1–7)
yrs. The median eGFR was 79.0 (IQR, 69.0–86.0) mls/min/
1.73 m
2 in control subjects and 48.5 (IQR, 40.0–61.0) mls/min/
1.73 m
2 in transplant subjects. Median albuminuria level was 0.94
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0.61–20.63) mg/mmol Cr in transplant subjects. Most transplant
patients (89%) were on triple immunosuppressant therapy
comprised of prednisone, a calcineurin inhibitor (tacrolimus or
cyclosporine), and either azathioprine or mycophenolate mofetil.
Urinary ACE2 Activity, Protein, and mRNA
As shown in Figure 1A, urinary ACE2 activity was significantly
increased in transplant patients, compared to control subjects
[control; median: 1.90 (IQR, 1.04–2.70) ng-eq/mg Cr610
2 vs
transplants; median: 3.65 (IQR, 1.13–9.35) ng-eq/mg Cr610
2;
p=0.003]. Similarly urinary ACE2 protein by ELISA was
significantly increased in transplant patients, compared to controls
(Figure 1B) [control; median: 1.41 (IQR, 0.00–4.49) ng/mg Cr vs
transplants; median: 8.04 (IQR, 0.00–21.11) ng/mg Cr;
p,0.001]. In 96% of unconcentrated urine samples from control
and 94% from transplant subjects, ACE2 was identified by western
analysis as a protein doublet of 120 kDa and 90 kDa. As with
urinary ACE2 activity and ELISA measurements, western
analyses revealed a significant increase in urinary ACE2 protein
in transplant patients compared to controls (Figure 1C: p=0.001).
Within the group of 100 transplant patients, multiple linear
regression using primary renal diseases as explanatory variables
revealed a significant association between the diagnosis of diabetic
nephropathy (n=21) and urinary ACE2 protein by ELISA or
western analyses (p,0.001 for both). In contrast, there was no
significant association between urinary ACE2 levels and other
primary causes of renal disease in these patients. Further studies
were performed on the association between diabetes mellitus and
urinary ACE2 in the transplant patients. Of the 100 transplant
patients, 38 had a diagnosis of diabetes mellitus listed on their
hospital chart. The majority of these patients were taking insulin
(31 out of 38, 81.6%), 6 (15.8%) were taking oral hypoglycemic
agents, and only 1 patient (2.6%) was on dietary therapy alone.
Transplant patients with diabetes (n=38) had significantly
higher levels of urinary ACE2 activity, compared to non-diabetic
(n=62) subjects [Figure 2A: diabetics; 8.75 (IQR, 3.09–15.54) vs
non-diabetics; 2.32 (IQR, 0.63–5.37) ng-eq/mg Cr610
2;
p,0.001]. Similarly, ACE2 protein levels by ELISA and western
analysis were significantly increased in diabetic subjects, compared
to non-diabetics (Figure 2B, C; p,0.001 vs non-diabetics for
both). In transplant patients with diabetes, both the 120 kDa and
the 90 kDa ACE2 protein bands were significantly increased on
westerns, compared to non-diabetics (p=0.002 vs non-diabetics
for the 120 kDa band, and p,0.001 vs non-diabetics for the
90 kDa band). Moreover, urinary ACE2 protein levels by ELISA
were significantly increased in subjects with diabetes pre-trans-
plant (n=21), compared to subjects who developed diabetes after
transplant (n=17; p=0.024).
The state of glycosylation of the urinary ACE2 proteins at
120 kDa and 90 kDa was studied by treating urine samples with
the deglycosylase enzyme PNGase F. Urinary ACE2 fragment
sizes were reduced to ,85 kDa and ,65 kDa by PNGase F
treatment, indicating that both fragments were originally glyco-
sylated (Figure 2D).
RNA was extracted from urinary pellets and subjected to real-
time PCR for ACE2. ACE2 mRNA was detected in 45% of urine
samples of transplant patients, with no significant difference
between diabetic [0.669 (IQR, 0.00–6.15) pg mRNA/mg
Cr610
25] and non-diabetic subjects [0.00 (IQR, 0.00–2.06) pg
mRNA/mg Cr610
25; p=0.091].
After adjusting for potential confounding factors [age, gender,
diabetes, eGFR, albuminuria, hypertension, and use of calcineurin
inhibitors] only diabetes was significantly associated with urinary
ACE2 activity (p=0.003) and protein levels (p,0.001, Table 2) in
transplant patients. An increase in urinary ACR was associated
with urinary ACE2 protein by ELISA (p=0.026), but not with
ACE2 activity or ACE2 protein by western. Female gender was
associated with higher urinary ACE2 mRNA levels in transplant
patients (p=0.004, Table 2).
Since the numbers of patients taking calcineurin inhibitors (95/
100 patients) were highly skewed (Table 1), multivariate analysis
was also performed with exclusion of this variable. This did not
alter the significance levels for any parameters reported in Table 2.
Urinary ACE Activity, Protein, and mRNA
Urinary ACE activity was detected in 65% of transplant patients
[median for all 100 patients: 1.17 (IQR, 0.00–3.43) ng-eq/mg
Cr610
2]. By western analysis, ACE was detected in 94% of urine
samples of transplant patients as a protein band of approximately
190 kDa, consistent with previous studies [18] (Figure 3). Urinary
ACE activity and protein levels were significantly increased in
diabetic transplant subjects, compared to non-diabetic patients
(Figure 3A,B; p=0.013, p=0.019, respectively). ACE mRNA was
detected in 65% of urine samples of transplant patients, with no
significant difference between diabetic [3.06 (IQR, 0.04–19.09) pg
mRNA/mg Cr610
25] and non-diabetic patients [0.77 (IQR,
0.00–13.16) pg mRNA/mg Cr610
25; p=0.18].
After adjusting for potential confounding variables, increased
urinary albumin/Cr was associated with urinary ACE protein by
western analysis in transplant patients (p,0.001, Table 2).
However, diabetes did not associate with increased urinary ACE
activity or ACE protein. Female gender and urinary albumin/Cr
Table 1. Subject demographic data.
Control (n=50) Patients (n=100)
Age (years) 45 (36–50) 54 (42–62)
Male gender (%) 26 65
eGFR (mls/min/1.73 m
2) 79.0 (69.0–86.0) 48.5 (40.0–61.0)
ACR (mg/mmol) 0.94 (0.67–1.43) 1.58 (0.61–20.63)
Diabetes % 0 38
Hypertension % 0 88
Years post-transplant N/A 3 (1–7)
Primary cause of renal
disease, %
Diabetic nephropathy N/A 21
Hypertension N/A 9
Polycystic kidney disease N/A 13
Glomerulonephritis N/A 41
Other N/A 16
Triple immunosuppression
use
a %
N/A 89
CNI (Cyclosporine or Tacrolimus) % N/A 95
Prednisone % N/A 97
Mycophenolate mofetil % N/A 90
Azathioprine % N/A 8
Sirolimus % N/A 3
Values are medians with interquartile range in parentheses. Abbreviations:
eGFR: estimated glomerular filtration rate, ACR: urine albumin to Cr ratio, CNI:
calcineurin inhibitor.
a calcineurin inhibitor, mycophenolate mofetil or
azathioprine, and corticosteroid. N/A: not applicable.
doi:10.1371/journal.pone.0037649.t001
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levels in transplant patients (Table 2).
Urinary Ang II and Ang-(1-7)
Transplant patient with diabetes had significantly higher levels of
urinary Ang II, compared to non-diabetics (Figure 4A: p=0.027).
Urinary Ang-(1-7) levels did not differ between the two groups
(Figure 4B: p=0.13). However, a significant positive linear
correlation was found between urinary ACE2 activity and urinary
Ang-(1-7) (r=0.260, p=0.009). In the multivariate analysis,
diabetes remained significantly associated with urinary Ang II
levels (p=0.042, Table 2). Neither diabetes, nor any other clinical
factor (eGFR, urinary albumin/Cr, etc.) was associated with
urinary Ang-(1-7) levels in the multiple linear regression model.
Discussion
The major finding of this study is that urinary ACE2 activity
and ACE2 protein are increased in kidney transplant recipients,
compared to healthy control subjects, and the presence of diabetes
strongly associates with urinary ACE2 levels in the patient
population, by multivariate analysis. Female gender associates
significantly with urinary ACE2 mRNA and ACE mRNA levels,
which are detected in 45% and 65% of transplant recipients,
respectively.
ACE2 is expressed at relatively high levels in the kidney,
particularly in the proximal tubule, and is thought to be
renoprotective via its ability to reduce Ang II levels. ACE2 also
increases production of Ang-(1-7), which can oppose the delete-
Figure 1. Urinary ACE2 activity and protein in control subjects and renal transplant (Tx) recipients. (A) Graph depicts box plots of
urinary ACE2 activity in control subjects (n=50) and Tx recipients (n=100). For each box plot, median values are indicated by the line within the box,
with value shown beside or above the line. The box represents 50% of the values (25
th and 75
th percentiles), with the upper bar representing the 90
th
percentile and the lower bar representing the 10
th percentile. Open circles indicate outliers. * p=0.003, Control vs Tx recipients. (B) Graph depicts box
plots of urinary ACE2 protein by ELISA in control subjects and Tx recipients. ** p,0.001, Control vs Tx recipients. (C) Graph depicts box plots of
urinary ACE2 protein by western analyses in control subjects and Tx recipients. Densitometry analysis was performed on both urinary ACE2 bands
(120 kDa and 90 kDa), and the sum of the two bands was used for quantitative comparisons. **p=0.001, Control vs Tx recipients.
doi:10.1371/journal.pone.0037649.g001
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activity in transplant recipients without diabetes (No Diabetes), or with diabetes (Diabetes). For each box plot, median values are indicated by the line
within the box, with value shown above the line. The box represents 50% of the values (25
th and 75
th percentiles), with the upper bar representing
the 90
th percentile and the lower bar representing the 10
th percentile. Open circles indicate outliers. * p,0.001, Diabetes vs. No Diabetes; n=62 (No
Diabetes), n=38 (Diabetes). (B) Graph depicts box plots of urinary ACE2 protein by ELISA in transplant recipients without diabetes (No Diabetes), or
with diabetes (Diabetes). *p,0.001, Diabetes vs. No Diabetes. (C) Graph depicts box plots of urinary ACE2 protein by western analysis in transplant
patients without diabetes (No Diabetes), or with diabetes (Diabetes). *p,0.001, Diabetes vs. No Diabetes. Above graph is representative immunoblot
for ACE2 in urine, showing bands at 120 kDa and 90 kDa. Densitometry analysis was performed on both bands, and the sum of the two bands was
used for quantitative comparisons. The protein bands for ACE2 in urine specimens were not observed when membranes were incubated with the
secondary antibody alone, bypassing the primary antibody step. Lanes 1–3, No Diabetes. Lanes 4–6, Diabetes. Lane 7: recombinant human ACE2
protein (hACE2), used as a positive control. (D) Representative immunoblot for urinary ACE2 treated without (2) or with (+) the deglycosylase enzyme
PNGase F. Lanes 1+,2 +,3 +, and 4+ show a reduction in the sizes of urinary ACE2 fragments to ,85 kDa and ,65 kDa in urine samples treated with
PNGase F. Lanes 1 and 2, No Diabetes. Lanes 3 and 4, Diabetes. Lane 5: recombinant human ACE2 protein (hACE2).
doi:10.1371/journal.pone.0037649.g002
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Kidney expression of ACE2 is reduced in experimental models,
including the remnant kidney model of CKD [16,20,21]. In
humans with diabetic nephropathy, expression of ACE2 is
decreased in glomeruli and proximal tubules [22], suggesting
a predisposition to Ang II-mediated injury.
Our results support the hypothesis that transplant patients with
diabetes exhibit increased urinary excretion of ACE2 protein. This
was independent of eGFR as determined by multivariate analysis.
Both soluble ACE2 and ACE have been detected in human urine
[10], and in humans with CKD, Mizuiri et al. reported increased
urinary levels of ACE2 protein by ELISA, compared to healthy
subjects [14]. Patients with diabetic nephropathy had higher
urinary levels of ACE2 than those without diabetic nephropathy,
and use of ACE inhibitor and/or angiotensin receptor blockers did
not affect urinary ACE2 levels [14]. In our study, no subjects were
taking inhibitors of the RAS. Using three independent assays for
urinary ACE2 (enzyme activity, ELISA, and immunoblot),
multiple linear regression revealed that diabetes was the only
variable consistently predictive of higher urinary ACE2 levels. Age
and gender had no influence on urinary ACE2 activity or protein
levels. Similarly, in patients with CKD Mizuiri et al. found no
difference in urinary ACE2 levels between males and females [14].
Although gender did not influence urinary ACE2 activity or
protein, in the present studies females had significantly higher
urinary ACE2 mRNA levels. The gene for ACE2 is located on the
X chromosome [2], and in the rat renal wrap model of
hypertension, intrarenal ACE2 activity and expression are up-
regulated by estrogens [23], raising the possibility that female
transplant recipients may express ACE2 mRNA at higher levels in
the kidney compared to males. Female gender was also associated
with higher urinary ACE mRNA levels, as was albuminuria, the
latter being in agreement with studies in patients with diabetic
nephropathy [24]. The cellular origin of urinary mRNA for ACE2
or ACE is unknown, although it has been speculated that proximal
tubular cells may be the source, since they express all components
of the RAS, and are found in the urine sediment [24]. However,
the physiological significance of urinary ACE2 or ACE mRNA
levels is unclear. In this regard, diabetes, albuminuria and eGFR
did not influence urinary ACE2 mRNA levels in our transplant
recipients, a result that differs from diabetic nephropathy patients,
where proteinuria was found to correlate positively with urinary
ACE2 mRNA, and eGFR to correlate negatively with ACE2
mRNA [24]. Factors related to transplant could therefore have an
independent influence on urinary ACE2 mRNA. As one
possibility, the use of immunosuppressive drugs in transplant
subjects might regulate shedding of cells expressing ACE2 mRNA
into the urine.
Urinary ACE2 protein could originate at least partly from
plasma (via filtration at the glomerulus), or it could be derived via
excretion from renal cells. Although Mizuiri et al. found higher
urinary ACE2 levels in CKD patients, there was no difference in
plasma ACE2 protein between CKD patients and healthy subjects
[14]. However, the CKD patients in their study had significant
albuminuria, suggesting that ACE2 may have leaked into the urine
across the glomerular barrier. In the present study, we found no
association between albuminuria and either urinary ACE2 activity
or protein levels by western analysis. The data suggest that urinary
ACE2 protein likely derives via shedding from cells along the
nephron, and not from filtration from plasma. In support of this
hypothesis, soluble ACE2 is shed from the plasma membrane in
cell culture systems, via cleavage at its ectodomain by the protease
enzyme ADAM-17 [11–13]. Interestingly, renal ADAM-17 is up-
regulated in Ang II-induced kidney injury [25], and de novo
expression occurs in human kidney disease, in proximal tubule,
podocytes, and mesangial cells [26]. Whether ADAM-17 is
activated in the transplant kidney in the presence of diabetes,
Table 2. Multiple linear regression adjusting for common variables in transplant recipients.
Dependent Variable Independent Variable Standardized Coefficient (b) 95% CI p value
ACE2 Activity
Diabetes 0.295 0.104, 0.487 0.003
ACE2 ELISA
Diabetes 0.365 0.183, 0.547 ,0.001
ACR 0.207 0.025, 0.389 0.026
ACE2 Western
Diabetes 0.332 0.143, 0.521 ,0.001
ACE2 mRNA
Gender (Female) 0.287 0.095, 0.479 0.004
ACE activity (none)
ACE Western
ACR 0.327 0.138, 0.516 ,0.001
ACE mRNA
Gender (Female) 0.222 0.033, 0.411 0.022
ACR 0.267 0.078, 0.456 0.006
Ang II
Diabetes 0.204 0.008, 0.400 0.042
Ang-(1-7) (none)
All analyses adjusted for eGFR, age, gender, albuminuria, diabetes, hypertension, and use of calcineurin inhibitors. Abbreviations: eGFR: estimated glomerular filtration
rate, ACR: urine albumin to Cr ratio.
doi:10.1371/journal.pone.0037649.t002
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further study.
Two bands for ACE2 were detected by immunoblot of urine
samples in the current study. One band was found at 120 kDA,
consistent with the full-length protein, and the other at 90 kDa,
which is likely a cleaved ACE2 fragment. Thus, the 90 kDa
Figure 3. Urinary ACE activity and protein in renal transplant
recipients: Effect of diabetes. (A) Graph depicts box plots of urinary
ACE activity in transplant recipients without diabetes (No Diabetes) or
with diabetes (Diabetes). For each box plot, median values are indicated
by the line within the box, with value shown above the line. The box
represents 50% of the values (25
th and 75
th percentiles), with the upper
bar representing the 90
th percentile and the lower bar representing the
10
th percentile. Open circles indicate outliers. * p=0.013, Diabetes vs
No Diabetes. (B) Graph shows box plots for densitometric analysis of
protein bands for urinary ACE, at 190 kDa, in transplant recipients
without diabetes (No Diabetes) or with diabetes (Diabetes). * p=0.019,
Diabetes vs No Diabetes. Representative ACE immunoblot on urine
specimens is shown above graph. In samples from mouse cortex, ACE
appeared as a single band at 170 kDa, as expected (mACE, lane 7) (5).
This blot was not used for densitometric quantitation of urinary ACE.
Protein bands corresponding to ACE were absent when membranes
were incubated with the secondary antibody alone. Lanes 1–3, No
Diabetes. Lanes 4–6, Diabetes. Lane 7: mouse kidney cortex, used as
a positive control.
doi:10.1371/journal.pone.0037649.g003
Figure 4. Urinary Ang II and Ang-(1-7). (A) Graph shows box plots
of RIA for Ang II in urine specimens from transplant recipients without
diabetes (no Diabetes) or with diabetes (Diabetes). For each box plot,
median values are indicated by the line within the box, with value
shown above the line. The box represents 50% of the values (25
th and
75
th percentiles), with the upper bar representing the 90
th percentile
and the lower bar representing the 10
th percentile. Open circles indicate
outliers. * p=0.027, Diabetes vs. No Diabetes. (B) Graph shows box
plots of EIA for Ang-(1-7) in urine specimens from transplant recipients
without or with diabetes. There was no significant difference between
the two groups (p=0.126).
doi:10.1371/journal.pone.0037649.g004
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length ACE2, since incubation with PNGase F resulted in a further
reduction in its size, as shown in Figure 2D. To determine if this
90 kDa fragment is generated by ADAM-17-mediated cleavage
of ACE2, further characterization is required, including use of
antibodies directed against the cytoplasmic carboxyterminus of
ACE2 (which may be lacking in this fragment), and/or direct
sequence analysis of the polypeptide. Furthermore, although
shedding of ACE2 fragments may occur via ADAM-17 in
transplant subjects, proteomic analysis has identified ACE2 as
one of the 1132 proteins present in urinary exosomes isolated from
human urine [27], suggesting that membrane-bound full-length
ACE2 may also be a source of urinary ACE2.
By multivariate analysis, diabetes was significantly associated
with urinary Ang II levels in transplant subjects, consistent with
intrarenal RAS activation in diabetes [28]. In this regard, although
diabetic patients had significantly higher urinary ACE activity and
ACE protein levels by immunoblot, this association was not
confirmed in the multivariate analysis. Finally, although diabetics
had higher urinary ACE2 activity and protein levels, there was no
significant association between diabetes and urinary levels of Ang-
(1-7) by multivariate analysis, suggesting that urinary Ang-(1-7)
may be influenced by other factors. A potential limitation of the
urinary angiotensin peptide measurements is that urine specimens
were not treated with protease inhibitors, which could have
affected the sensitivity for detecting differences. Interestingly,
however, we did observe a significant correlation between urinary
ACE2 activity and Ang-(1-7) levels.
Our study has a number of strengths, including the reliability
and reproducibility of the assays, the inclusion of data on mRNA,
protein, and ACE2/ACE products, and the use of multiple linear
regression to adjust for confounding variables. Limitations include
the relatively small number of subjects, the absence of plasma
ACE2 or ACE measurements, and the single time point for
urinary ACE2, ACE and peptide assays. Furthermore, it is
possible that diabetes alone may contribute to increased urinary
ACE2 levels, independent of transplant status. Studies in patients
with diabetes and normal kidney function are required to answer
this question. Larger studies are also needed to determine if
urinary ACE2 or ACE are biomarkers of transplant function or if
they may predict responsiveness to blockade of the RAS.
In summary, in renal transplant recipients diabetes is a strong
independent predictor of increased urinary levels of ACE2 activity
and protein. Our data further suggest that ACE2 may be shed into
the urine in transplant recipients, and could represent a marker to
assess the role of the kidney RAS in these patients.
Supporting Information
Text S1 Detailed methods for enzyme activity assays,
immunoblots, real-time PCR assays, and measurements
of Ang II and Ang-(1-7).
(DOC)
Acknowledgments
The authors thank Ms. Valerie Cronin, Ms. Judy Cheesman, and
Mr. Scott Mullen at the Kidney Research Centre for assistance with
recruitment of study subjects, collection of demographic data, and
preparation of protocols, and Ms. Julie Zhu for assistance with processing
of urine specimens.
Author Contributions
Conceived and designed the experiments: FX SH GK DJ DF CK KDB.
Performed the experiments: FX JZ KS DJ CK KDB. Analyzed the data:
FX SH GK JZ KDB. Wrote the paper: FX SH GK JZ DF CK KDB.
References
1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, et al. (2000) A
novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts
angiotensin I to angiotensin 1–9. Circ Res 87: 1–9.
2. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, et al. (2000) A human
homolog of angiotensin-converting enzyme. Cloning and functional expression
as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238–33243.
3. Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD (2005) The role of
angiotensin converting enzyme 2 in the generation of angiotensin 1–7 by rat
proximal tubules. Am J Physiol Renal Physiol 288: 353–362.
4. Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, et al.
(2007) Angiotensin metabolism in renal proximal tubules, urine, and serum of
sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol
Renal Physiol 292: 82–91.
5. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, et al. (2004) Increased
ACE 2 and decreased ACE protein in renal tubules from diabetic mice:
a renoprotective combination? Hypertension 43: 1120–1125.
6. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, et al. (2006) Loss of
angiotensin-converting enzyme-2 leads to the late development of angiotensin II-
dependent glomerulosclerosis. Am J Pathol 168: 1808–1820.
7. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, et al. (2007) Loss of
angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.
Am J Pathol 171: 438–451.
8. Wysocki J, Ye M, Rodriguez E, Gonza ´lez-Pacheco FR, Barrios C, et al. (2010)
Targeting the degradation of angiotensin II with recombinant angiotensin-
converting enzyme 2: prevention of angiotensin II-dependent hypertension.
Hypertension 55: 90–98.
9. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, et al. (2010) Human
recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes
59: 529–538.
10. Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, et al. (2005)
Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially
localized to the apical surface of polarized kidney cells. J Biol Chem 47:
39353–39362.
11. Iwata M, Silva Enciso JE, Greenberg BH (2009) Selective and specific regulation
of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis
factor alpha-converting enzyme. Am J Physiol Cell Physiol 297: 1318–1329.
12. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, et al. (2005)
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated
ectodomain shedding of the severe-acute respiratory syndrome-coronavirus
(SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem
280: 30113–30119.
13. Jia HP, Look DC, Tan P, Shi L, Hickey M, et al. (2009) Ectodomain shedding of
angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung
Cell Mol Physiol 297: 84–96.
14. Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, et al. (2011) Urinary ACE2 in
patients with CKD. Nephrology (Carlton) 16: 567–572.
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. (2006) Using
standardized serum creatinine values in the modification of diet in renal disease
study equation for estimating glomerular filtration rate. Annal Int Med 145:
247–254.
16. Dilauro M, Robertson S, Genest D, Burns KD (2010) The effect of ACE2 and
angiotensin-(1–7) in a mouse model of early chronic kidney disease. Am J Physiol
Renal Physiology 298: 1523–1532.
17. Hermann K, Rittweger R, Phillips MI, Ring J (1992) Presence of angiotensin
peptides in human urine. Clin Chem 38: 1768–1772.
18. Casarini DE, Plavinik FL, Zanella MT, Marson O, Krieger JE, et al. (2001)
Angiotensin converting enzymes from human urine of mild hypertensive
untreated patients resemble the N-terminal fragment of human angiotensin I-
converting enzyme. Int J Biochem Cell Biol 33: 75–85.
19. Su Z, Zimpelmann J, Burns KD (2006) Angiotensin-(1–7) inhibits angiotensin II-
stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int
69: 2212–2218.
20. Koitka A, Cooper ME, Thomas MC, Tikellis C (2008) Angiotensin converting
enzyme 2 in the kidney. Clin Exp Pharmacol Physiol 35: 420–425.
21. Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R (2008) Glomerular renin
angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats.
Transl Res 151: 208–216.
22. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM (2008)
Decreased glomerular and tubular expression of ACE2 in patients with type 2
diabetes and kidney disease. Kidney Int 74: 1610–1616.
23. Ji H, Menini S, Zheng W, Pesce C, Wu X, et al. (2008) Role of angiotensin-
converting enzyme 2 and angiotensin(1–7) in 17beta-oestradiol regulation of
renal pathology in renal wrap hypertension in rats. Exp Physiol 93: 648–657.
Urinary ACE2 in Renal Transplants
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e3764924. Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, et al. (2008) Urinary mRNA
expression of ACE and ACE2 in human type 2 diabetic nephropathy.
Diabetologia 51: 1062–1067.
25. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, et al. (2005) Angiotensin II
and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic
approach. Nature Med 8: 867–874.
26. Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, et al.
(2009) ADAM17 upregulation in human renal disease: a role in modulating
TGF-alpha availability? Am J Physiol Renal Physiol 297: 781–790.
27. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, et al. (2009)
Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc
Nephrol 20: 363–379.
28. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, et al. (2003) Renin-
angiotensin system activation and interstitial inflammation in human diabetic
nephropathy. Kidney Int Suppl 86: 64–70.
Urinary ACE2 in Renal Transplants
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37649